idiotype

Alizadeh has multiple issued and pending patents licensed to Foresight Diagnostics, CiberMed Inc. and Idiotype Vaccines.

These findings also inform upon the previous experience with idiotype therapy.

Idiotype vaccines seemed to provoke predominantly CD4 and/or humoral responses, consistent with our finding of selective MHC-II presentation of Ig antigens and CD4 Ig neoantigen-specific T cells27, 28.

Clinical trials of vaccine therapy targeting lymphoma Ig variable regions showed early promise, but three independent phase III trials of idiotype vaccine found either modest or no overall clinical benefit29, 30, 31.

Our results suggest that MHC presentation of variable-region epitopes is not equivalent across all individual lymphomas, raising the possibility that the patients who benefited from idiotype vaccination were those with active presentation of their Ig neoepitopes.